Literature DB >> 11403739

Pharmacologic treatment of fibromyalgia.

A Barkhuizen1.   

Abstract

Fibromyalgia is a chronic syndrome characterized by widespread pain, unrefreshed sleep, disturbed mood, and fatigue. Until such time as we have a clearer understanding of the trigger and/or pathophysiologic mechanisms producing these symptoms, pharmacologic treatment should be aimed at individual symptoms. Such treatment should ideally be offered as part of a multidisciplinary treatment program using both pharmacologic and nonpharmacologic treatment modalities. Critical components of any successful fibromyalgia treatment program include addressing physical fitness, work and other functional activities, and mental health, in addition to symptom-specific therapies. The main symptoms that should be addressed include pain, sleep disturbances including restless leg syndrome, mood disturbances, and fatigue. Pharmacologic therapy should also be considered for syndromes commonly associated with fibromyalgia including irritable bowel syndrome, interstitial cystitis, migraine headaches, temporomandibular joint dysfunction, dysequilibrium including neurally mediated hypotension, sicca syndrome, and growth hormone deficiency. This article provides general guidelines in initiating a successful pharmacologic treatment program for fibromyalgia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403739     DOI: 10.1007/s11916-001-0025-y

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  68 in total

Review 1.  Advances in the treatment of fibromyalgia: current status and future directions.

Authors:  G S Alarcón; L A Bradley
Journal:  Am J Med Sci       Date:  1998-06       Impact factor: 2.378

2.  The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain.

Authors:  A C Jung; T Staiger; M Sullivan
Journal:  J Gen Intern Med       Date:  1997-06       Impact factor: 5.128

3.  Sleep and musculoskeletal pain.

Authors:  H Moldofsky
Journal:  Am J Med       Date:  1986-09-29       Impact factor: 4.965

4.  Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial.

Authors:  S Carette; M J Bell; W J Reynolds; B Haraoui; G A McCain; V P Bykerk; S M Edworthy; M Baron; B E Koehler; A G Fam
Journal:  Arthritis Rheum       Date:  1994-01

5.  Comorbidity of fibromyalgia with medical and psychiatric disorders.

Authors:  J I Hudson; D L Goldenberg; H G Pope; P E Keck; L Schlesinger
Journal:  Am J Med       Date:  1992-04       Impact factor: 4.965

Review 6.  Pain: an overview.

Authors:  J D Loeser; R Melzack
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

7.  Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms.

Authors:  E Kosek; J Ekholm; P Hansson
Journal:  Pain       Date:  1996-12       Impact factor: 6.961

8.  A randomized controlled trial of citalopram in the treatment of fibromyalgia.

Authors:  Jesper Nørregaard; Helge Volkmann; Bente Danneskiold-Samstøe
Journal:  Pain       Date:  1995-06       Impact factor: 6.961

9.  Sleep intensity in fibromyalgia: focus on the microstructure of the sleep process.

Authors:  A M Drewes; K D Nielsen; S J Taagholt; K Bjerregård; L Svendsen; J Gade
Journal:  Br J Rheumatol       Date:  1995-07

Review 10.  Advances in fibromyalgia: possible role for central neurochemicals.

Authors:  I J Russell
Journal:  Am J Med Sci       Date:  1998-06       Impact factor: 2.378

View more
  1 in total

1.  High prevalence of restless legs syndrome in somatoform pain disorder.

Authors:  Martin Aigner; Wolfgang Prause; Marion Freidl; Maria Weiss; Shahriar Izadi; Michael Bach; Bernd Saletu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-02       Impact factor: 5.270

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.